194 related articles for article (PubMed ID: 24395718)
1. Fluvastatin as a micropore lifetime enhancer for sustained delivery across microneedle-treated skin.
Ghosh P; Brogden NK; Stinchcomb AL
J Pharm Sci; 2014 Feb; 103(2):652-60. PubMed ID: 24395718
[TBL] [Abstract][Full Text] [Related]
2. Development of a codrug approach for sustained drug delivery across microneedle-treated skin.
Ghosh P; Pinninti RR; Hammell DC; Paudel KS; Stinchcomb AL
J Pharm Sci; 2013 May; 102(5):1458-67. PubMed ID: 23417751
[TBL] [Abstract][Full Text] [Related]
3. Naltrexone salt selection for enhanced transdermal permeation through microneedle-treated skin.
Milewski M; Pinninti RR; Stinchcomb AL
J Pharm Sci; 2012 Aug; 101(8):2777-86. PubMed ID: 22628183
[TBL] [Abstract][Full Text] [Related]
4. Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin.
Banks SL; Paudel KS; Brogden NK; Loftin CD; Stinchcomb AL
Pharm Res; 2011 May; 28(5):1211-9. PubMed ID: 21301935
[TBL] [Abstract][Full Text] [Related]
5. Metabolic approaches to enhance transdermal drug delivery. 1. Effect of lipid synthesis inhibitors.
Tsai JC; Guy RH; Thornfeldt CR; Gao WN; Feingold KR; Elias PM
J Pharm Sci; 1996 Jun; 85(6):643-8. PubMed ID: 8773963
[TBL] [Abstract][Full Text] [Related]
6. Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride.
Milewski M; Stinchcomb AL
Pharm Res; 2011 Jan; 28(1):124-34. PubMed ID: 20577787
[TBL] [Abstract][Full Text] [Related]
7. Controlled delivery of ropinirole hydrochloride through skin using modulated iontophoresis and microneedles.
Singh ND; Banga AK
J Drug Target; 2013 May; 21(4):354-66. PubMed ID: 23311703
[TBL] [Abstract][Full Text] [Related]
8. Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans.
Brogden NK; Banks SL; Crofford LJ; Stinchcomb AL
Pharm Res; 2013 Aug; 30(8):1947-55. PubMed ID: 23761054
[TBL] [Abstract][Full Text] [Related]
9. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs.
Banks SL; Pinninti RR; Gill HS; Paudel KS; Crooks PA; Brogden NK; Prausnitz MR; Stinchcomb AL
J Pharm Sci; 2010 Jul; 99(7):3072-80. PubMed ID: 20166200
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo studies for the passive transdermal delivery of low-dose naltrexone from a cream; detection of naltrexone and its active metabolite, 6β-naltrexol, using a novel LC Q-ToF MS assay.
Dodou K; Armstrong A; Kelly I; Wilkinson S; Carr K; Shattock P; Whiteley P
Pharm Dev Technol; 2015; 20(6):694-701. PubMed ID: 24785567
[TBL] [Abstract][Full Text] [Related]
11. Transdermal delivery of naltrexone and its active metabolite 6-beta-naltrexol in human skin in vitro and guinea pigs in vivo.
Paudel KS; Nalluri BN; Hammell DC; Valiveti S; Kiptoo P; Hamad MO; Crooks PA; Stinchcomb AL
J Pharm Sci; 2005 Sep; 94(9):1965-75. PubMed ID: 16052561
[TBL] [Abstract][Full Text] [Related]
12. Micropore closure kinetics are delayed following microneedle insertion in elderly subjects.
Kelchen MN; Siefers KJ; Converse CC; Farley MJ; Holdren GO; Brogden NK
J Control Release; 2016 Mar; 225():294-300. PubMed ID: 26829102
[TBL] [Abstract][Full Text] [Related]
13. A new paradigm for numerical simulation of microneedle-based drug delivery aided by histology of microneedle-pierced skin.
Han T; Das DB
J Pharm Sci; 2015 Jun; 104(6):1993-2007. PubMed ID: 25821048
[TBL] [Abstract][Full Text] [Related]
14. Design of a Dissolving Microneedle Platform for Transdermal Delivery of a Fixed-Dose Combination of Cardiovascular Drugs.
Quinn HL; Bonham L; Hughes CM; Donnelly RF
J Pharm Sci; 2015 Oct; 104(10):3490-500. PubMed ID: 26149914
[TBL] [Abstract][Full Text] [Related]
15. A duplex "Gemini" prodrug of naltrexone for transdermal delivery.
Hammell DC; Hamad M; Vaddi HK; Crooks PA; Stinchcomb AL
J Control Release; 2004 Jun; 97(2):283-90. PubMed ID: 15196755
[TBL] [Abstract][Full Text] [Related]
16. Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin.
Milewski M; Brogden NK; Stinchcomb AL
Expert Opin Drug Deliv; 2010 May; 7(5):617-29. PubMed ID: 20205604
[TBL] [Abstract][Full Text] [Related]
17. Effect of controlled laser microporation on drug transport kinetics into and across the skin.
Bachhav YG; Summer S; Heinrich A; Bragagna T; Böhler C; Kalia YN
J Control Release; 2010 Aug; 146(1):31-6. PubMed ID: 20678988
[TBL] [Abstract][Full Text] [Related]
18. Flux across [corrected] microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro.
Banks SL; Pinninti RR; Gill HS; Crooks PA; Prausnitz MR; Stinchcomb AL
Pharm Res; 2008 Jul; 25(7):1677-85. PubMed ID: 18449628
[TBL] [Abstract][Full Text] [Related]
19. Optimizing microneedle arrays to increase skin permeability for transdermal drug delivery.
Al-Qallaf B; Das DB
Ann N Y Acad Sci; 2009 Apr; 1161():83-94. PubMed ID: 19426308
[TBL] [Abstract][Full Text] [Related]
20. Large Size Microneedle Patch to Deliver Lidocaine through Skin.
Kathuria H; Li H; Pan J; Lim SH; Kochhar JS; Wu C; Kang L
Pharm Res; 2016 Nov; 33(11):2653-67. PubMed ID: 27401408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
